X4 PHARMACEUTICALS, INC Amortization
X4 PHARMACEUTICALS, INC (XFOR) reported Amortization of $289.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2025-05-01
- X4 PHARMACEUTICALS, INC amortization for the quarter ending 2025-03-31 was $289.00K, a 366.13% increase year-over-year.
- X4 PHARMACEUTICALS, INC amortization for the quarter ending 2024-09-30 was $80.00K, a 23.08% decline year-over-year.
- X4 PHARMACEUTICALS, INC amortization for the quarter ending 2024-06-30 was $69.00K.
- X4 PHARMACEUTICALS, INC amortization for the quarter ending 2024-03-31 was $62.00K.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month |
|---|---|---|---|
| 2025-03-31 | $289.00K 10-Q · filed 2025-05-01 | ||
| 2024-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $149.00K derived: sum of 2 quarters · filed 2024-11-13 | $211.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $131.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $62.00K 10-Q · filed 2025-05-01 | ||
| 2023-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $357.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $253.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |